FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, namely to pharmacology and cardiology, and concerns endothelial dysfunction correction. That is ensured by administering a therapeutic agent containing an activated-potentiated form of antibodies to the endothelial synthase of nitrogen oxide in a complex of an activated-potentiated form of antibodies to the C-terminal fragment of the AT1 angiotensin II receptor.
EFFECT: administering this agent provides the effective endothelial dysfunction correction by the synergistic effect of its ingredients.
6 cl, 1 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AGENT FOR ENDOTHELIAL DYSFUNCTION CORRECTION | 2011 |
|
RU2543332C2 |
| METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION | 2011 |
|
RU2527689C2 |
| METHOD FOR ENDOTHELIAL DYSFUNCTION CORRECTION | 2011 |
|
RU2542403C2 |
| METHOD OF TREATING CHRONIC CARDIAC FAILURE AND PHARMACEUTICAL COMPOSITION FOR TREATING CHRONIC CARDIAC FAILURE | 2011 |
|
RU2523451C2 |
| METHOD FOR INCREASE OF PHARMACOLOGICAL ACTIVITY OF ACTIVE AGENT OF DRUG PREPARATION AND PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2526153C2 |
| METHOD OF TREATMENT AND PREVENTION OF ARTERIAL HYPERTENSION AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ARTERIAL HYPERTENSION | 2010 |
|
RU2525156C2 |
| METHOD FOR INCREASING PHARMACOLOGICAL ACTIVITY OF ACTIVE SUBSTANCE OF MEDICINAL PRODUCT AND PHARMACEUTICAL COMPOSITION | 2014 |
|
RU2572706C1 |
| MEDICATION FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION | 2011 |
|
RU2536228C2 |
| METHOD OF TREATING CHRONIC HEART FAILURE AND PHARMACEUTICAL COMPOSITION FOR COMPLEX THERAPY OF CHRONIC HEART FAILURE | 2010 |
|
RU2525155C2 |
| THERAPEUTIC AGENT FOR ENDOTHELIAL DYSFUNCTION CORRECTION | 2011 |
|
RU2500424C2 |
